Anthera Pharmaceuticals Completes Interim Analysis of PEARL-SC Clinical Trial with Blisibimod

Anthera Pharmaceuticals, Inc.

today announced the continuation of the Phase 2b PEARL-SC clinical study following an interim analysis of all safety and efficacy data. As part of the ongoing safety monitoring of the PEARL-SC clinical study, the Company's Data Safety Monitoring Board met for the fourth time since the beginning of the study to review all available patient safety data. Following the analysis, the DSMB recommended the study proceed as planned without modification.